アリゾナ州における非小細胞肺癌の臨床試験
アリゾナ州内の拠点で、非小細胞肺癌に関する66件の研究が参加者を募集しています。
アリゾナ州内の都市
- Phoenix20件の研究
- Tucson17件の研究
- Scottsdale15件の研究
- Gilbert12件の研究
- Goodyear8件の研究
- Chandler5件の研究
- Bullhead City4件の研究
- Glendale3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Banner Boswell Medical Center, Sun City
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- HonorHealth Research Institute, Scottsdale
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07751042Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #67, Phoenix
- Exelixis Clinical Site #1, Tucson
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06996782A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Mohtaseb Cancer Center & Blood Disorders, Bullhead City
- Palo Verde Hematology Oncology, Glendale
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Palo Verde Hematology Oncology, Glendale
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Pioneer Research Center, Bullhead City
- Ironwood Cancer & Research Centers, Chandler
- Ironwood Cancer & Research Centers, Gilbert
- 他6件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- City of Hope Phoenix, Goodyear
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Cancer Treatment Centers of America, Phoenix, Goodyear
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06170788Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- City of Hope, Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Pan-tumor MRD Study
- Mohtaseb Cancer Center and Blood Disorders, Bullhead City
- Cancer & Blood Specialists of Arizona, Casa Grande
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Southern Arizona VA Health Care System, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Ironwood Cancer and Research Center /ID# 276370, Chandler
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06568939Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Banner MD Anderson Cancer Center, Gilbert
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
被験者募集中第1/2相
18歳〜99歳 · 全性別 · 2026/09/22更新 · NCT06814496A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- HonorHealth Research Institute, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07705334Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Chandler
- Clinical Study Site, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Banner Health- MD Anderson Cancer Center, Gilbert
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-556-A, Goodyear
- USOR - Arizona Oncology - Prescott Valley, Prescott Valley
- Local Institution - 007-568-A, Safford
- 他5件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Study of KK2269 in Adult Participants With Solid Tumors
- Mayo Clinic Arizona, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06266299A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- City of Hope - Phoenix, Goodyear
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Banner MD Anderson Cancer Center, Gilbert
- Banner University Medical Center Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- HonorHealth Research Institute, Scottsdale
- Mayo Scottsdale, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07361562A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Chandler
- Research Site, Gilbert
- Research Site, Goodyear
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07291037Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Mayo Clinic, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT05245500A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Mayo Clinic Arizona, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Mayo Clinic Arizona, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06892548A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- HonorHealth Research Institute, Scottsdale
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/08/19更新 · NCT07636785Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Mayo Clinic Hospital in Arizona, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06500481A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Mayo Clinic Hospital - Arizona, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366AOH1996 for the Treatment of Refractory Solid Tumors
- Honor Health Research and Innovation Institute, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT05227326A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Mayo Clinic Hospital, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT06179160ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。